

# Eco Animal Health Group Plc

17:43 20 Jul 2012

## Eco Animal Health results reveal major increase in profits

Eco Animal Health (LON:EAH) today revealed a major increase in profits and earnings for the 12 months ended March 31 2012.

The veterinary drug company increased profit 31.8 per cent to 2.6 million from £2 million, while earnings per share rose 41.6 per cent to 4.19p from 2.96. The company ended the year with £9.5 million in net cash and it now plans to up its dividend by 25 per cent to 3.75p.

The company said that the strong start to the second half of the year, revealed in the interims, was maintained. And the group's fortunes have been boosted further by the US approval of its lead product Aivlosin - a water soluble antibiotic for pigs.

This is expected to have significant impact as it opens the door to a major market but, financially, this boost isn't likely to start showing on the group's figures until next year as it will need a little time for the product to build momentum.

"ECO Animal Health Group has delivered another strong set of results for the year ended 31 March 2012 and the current year has started well," said chairman Peter Lawrence.

"We are confident that the long awaited marketing authorisations in the US and Canada will have a major positive effect on the development of ECO, although it will be some months before the product launches gain momentum. We do not expect a noticeable impact on our financial performance until next year.

"ECO is very well placed to further broaden its product ranges and its global reach will ensure that it capitalises on opportunities as they arise in all the Company's major markets. The Company is set for an exciting future and looks forward to maximising value for shareholders."

Robin Campbell, analyst at Merchant Securities, says the group's sales dynamics in the second half of the year were impressive – it delivered 11 per cent year on year sales growth in the period.


"This accelerating trend is encouraging and was achieved in tough global markets where pricing pressures intensified during the year, reflecting the generally difficult environment."

The analyst highlights that Eco records strong growth in Latin America and Asia and despite tough conditions in Europe it managed a 'very encouraging' growth of more than 30 per cent.

**Price:** 205

**Market Cap:** £138.47 m

### 1 Year Share Price Graph



April 2019 September 2019 March 2020

### Share Information

**Code:** EAH

**Listing:** AIM

**52 week High Low**  
470 90

**Sector:** Pharma & Biotech

**Website:**  
[www.ecoanimalhealthgroupplc.com](http://www.ecoanimalhealthgroupplc.com)

### Company Synopsis:

*ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Our products for these growth markets promote well-being in animals. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.*

[action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.